# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN-TD
- Date: 1964-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrice Fontenot, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Short of breath on stairs and on stage for about three months, with a dry cough, tiredness and tightness in the chest; she runs out of breath in the middle of long phrases; twice her heart has raced and she felt faint while singing **S**
- She was told after an operation twelve years ago that she had sarcoidosis; no record of that operation is available to this clinic, and she wants a clear answer and a plan that a working singer can keep **S**
- Her spring concerts and recording sessions are booked; she does not want to cancel unless she has to, and she needs her voice **S**

## Your goals

- Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation. Target: 1964-03-09. Recorded outcome: EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks. **S**
- Calcium in the normal range within three months. Target: 1964-05-11. Recorded outcome: Calcium 9.6 mg/dL after nine weeks of treatment. **S**
- FVC and DLCO improved by at least 10 percent of predicted within six months. Target: 1964-08-24. Recorded outcome: FVC 74 to 90 percent and DLCO 62 to 76 percent of predicted. **S**
- No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better. Target: 1964-08-24. Recorded outcome: Myocardial uptake resolved; ejection fraction 54 percent from 47. **S**
- Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent. Target: 1964-08-24. Recorded outcome: Prednisone 10 mg at six months and tapering. **S**
- Back on stage with a schedule she can sustain, with her voice protected. Target: 1964-08-24. Recorded outcome: Two concerts a week since late spring; a longer autumn tour planned. **S**

## What we agreed to do

- Pulmonology (sarcoidosis) consultation within two weeks, with EBUS-guided lymph node sampling arranged directly from the referral, to confirm the diagnosis and plan treatment. Guideline: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021) **S**
- Diagnosis of suspected sarcoidosis: chest radiograph and CT of the chest, tissue by EBUS-guided needle aspiration rather than mediastinoscopy, stains and cultures for mycobacteria and fungi, an interferon-gamma release assay and HIV test to exclude other causes; serum ACE is not used to make or exclude the diagnosis. Guideline: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020) **S**
- Screening every patient with suspected sarcoidosis for other organ involvement: ECG, serum calcium with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, creatinine, liver tests and alkaline phosphatase, complete blood count, TSH, and an eye examination; stop the calcium and vitamin D supplement while calcium is high. Guideline: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020) **S**
- Cardiac evaluation for suspected cardiac sarcoidosis (abnormal ECG and palpitations): 24-hour Holter monitoring, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with a dietary preparation, all before glucocorticoids begin; cardiology and electrophysiology review. Guideline: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024) **S**
- Treatment of cardiac and pulmonary sarcoidosis: prednisone 40 mg daily, tapered over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly (increased to 20 mg) and folic acid, continued for at least a year for cardiac disease; repeat FDG-PET after about six months. Guideline: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024) **S**
- Methotrexate safety: hepatitis B and C screening before starting, blood count, liver tests and creatinine every two to four weeks for the first three months and then every eight to twelve weeks, no alcohol, and no trimethoprim-sulfamethoxazole while on methotrexate. Guideline: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012) **S**
- Glucocorticoid protection: bone density scan and FRAX, alendronate weekly, dietary calcium only (no supplements while calcium was high), vitamin D replaced cautiously once calcium is normal, with calcium rechecked; atovaquone pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate; glucose, blood pressure, weight, mood, sleep and eye pressure checks. Guideline: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026) **S**
- Vaccination before immunosuppression: PCV20, recombinant zoster vaccine, hepatitis B vaccine for a non-immune adult, influenza and COVID-19 vaccines; no live vaccines while on prednisone and methotrexate. Guideline: Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Arrhythmia risk: metoprolol for ventricular ectopy; electrophysiology study for a left ventricular ejection fraction above 35 percent with scar on MRI and nonsustained ventricular tachycardia, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced; remote device monitoring, including on tour. Guideline: Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024) **S**
- Performing and travel: concerts paused until the defibrillator wound has healed and the first device check is done, then a lighter schedule with rest days, voice care, and a travel letter with her device card and medicine list; no driving for one week after the implant. Guideline: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014) **S**
- Depression screening at each phase, plain explanations with written information, and support she chooses; she decides who receives each note. Guideline: Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 1964-02-09: Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood tests **S**
- 1964-02-23: EBUS result: sarcoidosis; pulmonology consultation, lung function, screening for other organ involvement, and cardiac tests **S**
- 1964-03-09: Cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referral **S**
- 1964-05-11: Nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule **S**
- 1964-08-24: Six months of treatment: repeat FDG-PET, steroid taper, and plans for touring **S**
- 1964-10-05: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
